MAPT (Ab-214) Antibody

What is the MAPT (Ab-214) Antibody and what epitope does it recognize?

The MAPT (Ab-214) Antibody is a rabbit polyclonal antibody that specifically recognizes a peptide sequence around amino acids 212-216 (T-P-S-L-P) derived from human Tau protein . This antibody targets the microtubule-associated protein tau (MAPT), also known as neurofibrillary tangle protein or PHF-tau . The antibody is produced by immunizing rabbits with synthetic peptide and KLH conjugates, then purified via affinity chromatography using epitope-specific peptide . MAPT is a critical protein that promotes microtubule assembly and stability, and is involved in maintaining neuronal polarity .

What applications is this antibody validated for?

The MAPT (Ab-214) Antibody has been validated for the following applications:

The antibody has been successfully used in immunofluorescence staining of methanol-fixed HeLa cells as demonstrated in product validation images . Some vendors may also indicate the antibody's utility in Western blot applications, though specific validation for this application varies between manufacturers .

How should the MAPT (Ab-214) Antibody be stored and handled?

For optimal performance and longevity, the MAPT (Ab-214) Antibody should be stored according to manufacturer's guidelines:

• The antibody is typically supplied at 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150mM NaCl, 0.02% sodium azide, and 50% glycerol .

• Upon receipt, store at -20°C or -80°C for long-term storage .

• After reconstitution (if supplied lyophilized), the antibody can be stored at 4°C for one month or aliquoted and stored frozen at -20°C for up to six months .

• Avoid repeated freeze-thaw cycles to maintain antibody integrity and performance .

• Before use, briefly centrifuge the antibody solution to collect all material at the bottom of the tube.

What positive controls should be used when validating this antibody?

For proper validation of the MAPT (Ab-214) Antibody, the following positive controls have been confirmed effective:

• For Western blot: Rat brain tissue lysate, mouse brain tissue lysate, HT1080 whole cell lysate, and MCF-7 whole cell lysate have all shown specific binding at the expected molecular weight of approximately 79 kDa .

• For Immunofluorescence: Methanol-fixed HeLa cells have demonstrated positive staining .

When establishing the antibody in a new experimental system, positive controls should be run alongside experimental samples to confirm specific detection and appropriate experimental conditions.

Is MAPT (Ab-214) Antibody cross-reactive across different species?

The MAPT (Ab-214) Antibody demonstrates strong cross-reactivity across multiple species:

• Confirmed reactivity: Human, mouse, and rat samples have been validated for detection with this antibody .

• Potential cross-reactivity: While not explicitly tested for all primates, there is a good probability of cross-reactivity with primate tissues given the conservation of the epitope sequence .

• Expression patterns: MAPT expression has been documented in various tissues including brain, cervix carcinoma, erythroleukemia, fetal brain, leukemic T-cells, and liver across these species .

This cross-species reactivity makes the antibody particularly valuable for comparative studies between human samples and animal models of tauopathies.

How can MAPT (Ab-214) Antibody be used in combination with phospho-specific tau antibodies in tauopathy research?

For comprehensive tauopathy research, MAPT (Ab-214) Antibody can be strategically paired with phospho-specific antibodies:

The MAPT (Ab-214) Antibody recognizes a non-phospho-specific epitope of tau, making it ideal for detecting total tau levels regardless of phosphorylation state. In contrast, phospho-specific antibodies like AT8 (pSer202/pThr205), PHF-1 (pSer396/pSer404), and pS422 specifically detect pathological phosphorylation states associated with tauopathies .

Research has shown that in mouse models expressing human tau (MAPT KI) with Aβ-amyloidosis, phospho-specific antibodies can detect elevated tau phosphorylation while total tau antibodies like MAPT (Ab-214) provide baseline measurements . This dual approach enables:

• Calculation of the phosphorylated:total tau ratio, a more informative metric than either measurement alone

• Normalization of phosphorylation changes to account for variations in total tau expression

• Distinguishing between therapeutic effects on tau expression versus pathological phosphorylation

• Tracking disease progression through changes in both tau levels and its post-translational modifications

For maximal information, consider implementing multiple phospho-tau antibodies targeting different epitopes alongside MAPT (Ab-214) in serial sections or multiplexed immunostaining approaches.

What considerations should be made when using MAPT (Ab-214) Antibody in antisense oligonucleotide (ASO) tau reduction studies?

The MAPT (Ab-214) Antibody can be valuable for monitoring therapeutic tau reduction in ASO studies, with several important methodological considerations:

Recent research has developed ASOs targeting MAPT mRNA, achieving significant tau protein reduction (up to 55% in mouse models and 80% in non-human primates) . When using MAPT (Ab-214) to assess therapeutic efficacy, researchers should consider:

How should MAPT (Ab-214) Antibody be optimized for use in humanized tau mouse models?

When employing MAPT (Ab-214) Antibody in humanized tau mouse models, several optimization steps are essential:

Humanized MAPT knock-in mice, such as those described in recent studies, represent valuable models for tauopathy research, particularly when combined with amyloidosis models . For optimal results with MAPT (Ab-214) Antibody in these models:

• Dilution optimization: Humanized models may express tau at different levels than wild-type mice. Test a range of antibody dilutions (starting with 1:100-1:200 for IF) to determine optimal signal-to-noise ratio for your specific model.

• Protocol modifications based on experimental design:

  • For co-staining with Aβ plaque markers, consider sequential staining protocols to prevent antibody cross-reactivity

  • When comparing phosphorylation levels between genotypes, maintain identical antibody concentrations, incubation times, and development conditions

  • For dystrophic neurite visualization, optimize tissue sectioning thickness (typically 10-30 μm)

• Controls selection: Include appropriate controls for each experiment:

  • Wild-type mice (negative control for human tau)

  • Single MAPT KI mice (baseline human tau expression)

  • APP/MAPT double KI mice (for pathological interactions)

  • Established tauopathy models like P301S-tau transgenic mice (positive control for pathology)

• Comparative assessment: Consider using both MAPT (Ab-214) and phospho-specific antibodies to distinguish between changes in total tau expression versus pathological modifications in your model.

What methodological considerations should be made when using MAPT (Ab-214) Antibody for immunofluorescence co-staining experiments?

Successful immunofluorescence co-staining with MAPT (Ab-214) Antibody requires careful methodological planning:

• Primary antibody compatibility: Since MAPT (Ab-214) is a rabbit polyclonal antibody, it should be paired with primary antibodies raised in different host species (mouse, goat, chicken, etc.) to prevent secondary antibody cross-reactivity. This is particularly important when studying tau's interactions with other proteins like tubulin or other cytoskeletal components.

• Fixation optimization: The MAPT (Ab-214) Antibody has been validated with methanol fixation in HeLa cells , but different fixation protocols may be needed depending on the experimental question:

  • Methanol fixation: Good for cytoskeletal proteins but may disrupt membrane structures

  • Paraformaldehyde: Better preserves cellular morphology but may require antigen retrieval

  • Glutaraldehyde: Superior ultrastructural preservation but often requires more aggressive antigen retrieval

• Signal amplification considerations: For detecting low-abundance tau forms or in regions with limited expression:

  • Consider biotin-streptavidin amplification systems

  • Implement tyramide signal amplification where appropriate

  • Optimize exposure settings independently for each fluorophore

• Controls for co-localization studies:

  • Include single-stained samples for each antibody to assess bleed-through

  • Use co-localization coefficients (Pearson's, Manders') for quantitative analysis

  • Include biological negative controls where one protein is absent or significantly reduced

• Image acquisition parameters: For meaningful quantitative comparison between samples:

  • Maintain identical microscope settings across experimental groups

  • Perform z-stack imaging to capture the full spatial distribution of tau

  • Consider spectral unmixing for closely overlapping fluorophores

How does MAPT (Ab-214) Antibody perform in multi-step antibody validation protocols for tau research?

Comprehensive validation of MAPT (Ab-214) Antibody should follow a multi-step approach to ensure reliability in tau research:

The field of antibody developability has established rigorous validation frameworks that should be applied to MAPT (Ab-214) Antibody before employing it in critical research . A complete validation protocol includes:

• Knockout/knockdown validation:

  • Test the antibody in MAPT knockout tissues or CRISPR-modified cell lines

  • Implement siRNA knockdown of tau to demonstrate signal reduction

  • Compare with ASO-treated samples showing tau reduction

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide (aa.212-216 of tau)

  • Observe signal elimination in blocked samples compared to unblocked controls

  • Include non-specific peptide controls to confirm specificity

• Cross-platform validation matrix:

• Orthogonal antibody comparison:

  • Compare staining patterns with other validated tau antibodies targeting different epitopes

  • Confirm similar but not identical distribution patterns based on epitope accessibility

  • Document any discrepancies for specific experimental contexts

This comprehensive validation approach, adapted from antibody developability workflows used in therapeutic antibody development , ensures reliable results in critical tau research applications.

What are the biophysical and analytical considerations when characterizing MAPT (Ab-214) Antibody for specific experimental systems?

When characterizing MAPT (Ab-214) Antibody for specialized experimental systems, researchers should consider several biophysical and analytical parameters:

Drawing from principles of antibody developability assessment , key parameters to evaluate include:

• Colloidal properties:

  • Assess aggregation propensity under experimental conditions

  • Evaluate self-interaction potential that could affect binding kinetics

  • Measure viscosity in concentrated preparations for microinjection studies

• Thermal stability characterization:

  • Determine melting temperature (Tm) to ensure stability during experimental procedures

  • Assess freeze-thaw stability for long-term storage and repeated use

  • Evaluate pH sensitivity relevant to your experimental system

• Binding kinetics analysis:

  • Measure kon and koff rates using surface plasmon resonance

  • Determine KD values across temperature ranges relevant to your experiments

  • Compare affinity for recombinant versus native tau proteins

• Epitope accessibility in different experimental contexts:

  • Evaluate epitope masking in different fixation/permeabilization protocols

  • Assess recognition of tau in different conformational states

  • Determine the impact of tau-binding proteins on epitope recognition

• Analytical ultracentrifugation data:

  • Confirm antibody homogeneity and appropriate molecular weight

  • Detect potential aggregation or fragmentation

  • Ensure batch-to-batch consistency for long-term studies

These characterization steps are particularly important when using the antibody in novel applications or specialized experimental systems beyond the standard validated uses.

How should experimental designs with MAPT (Ab-214) Antibody be structured for statistical validity?

When designing experiments with MAPT (Ab-214) Antibody, proper statistical considerations are essential for meaningful results:

Drawing from principles of experimental design , researchers should implement:

• Randomized Complete Block Design (RCB) when testing MAPT antibody performance across:

  • Multiple tissue types

  • Different fixation protocols

  • Various disease models

This approach helps control for experimental variability by grouping similar experimental units into blocks .

• Sample size determination:

  • For preliminary assay validation: minimum n=3-5 per group

  • For comparing tau levels between experimental groups: power analysis based on expected effect size

  • For correlative studies with clinical outcomes: sample size based on established statistical power requirements

• Blocking factors to consider:

  • Animal age/sex

  • Tissue processing batch

  • Antibody lot number

  • Observer/analyst (for subjective measurements)

• Statistical analysis approaches:

  • For continuous measures (fluorescence intensity): ANOVA with appropriate post-hoc tests

  • For ordinal data (pathology scoring): non-parametric tests

  • For correlative analyses: regression models with appropriate transformations

• Experimental controls inclusion:

  • Technical replicates to assess method precision

  • Biological replicates to assess population variability

  • Positive and negative controls for each experimental run

Following these statistical design principles ensures robust, reproducible findings in tau research using MAPT (Ab-214) Antibody.

What are optimal strategies for troubleshooting variability in MAPT (Ab-214) Antibody performance?

When encountering variability in MAPT (Ab-214) Antibody performance, implement these systematic troubleshooting strategies:

• Source of variation identification:

  • Antibody factors: lot variability, storage conditions, freeze-thaw cycles

  • Sample factors: fixation time, processing methods, tissue quality

  • Technical factors: incubation temperature fluctuations, buffer composition

• Systematic optimization matrix:

• Standardization measures:

  • Use internal reference controls in each experiment

  • Implement normalization strategies for quantitative analyses

  • Develop standard curves using recombinant tau when applicable

• Antibody validation verification:

  • Confirm epitope integrity in your experimental system

  • Verify species cross-reactivity with your specific samples

  • Test new antibody lots against previous successful lots

• Technical recommendations for specific issues:

  • For high background: Increase blocking time/concentration, add 0.1-0.3% Triton X-100

  • For weak signal: Optimize antigen retrieval, increase antibody concentration

  • For non-specific binding: Include additional washing steps, test IgG blocking

Implementing this structured approach helps isolate variables and systematically improve experimental reproducibility.

How can MAPT (Ab-214) Antibody be effectively used in studying tau-targeted therapeutics?

The MAPT (Ab-214) Antibody offers valuable applications in tau-targeted therapeutic research through these methodological approaches:

• Therapeutic efficacy assessment:

  • Quantify total tau reduction following antisense oligonucleotide treatment

  • Monitor tau levels after small molecule therapeutics administration

  • Compare regional brain differences in therapeutic response

• Mechanistic investigations:

  • Study differential effects on specific tau isoforms

  • Examine subcellular redistribution of tau following treatment

  • Analyze tau turnover rates through pulse-chase experiments

• Experimental design for therapeutic studies:

  • Baseline measurements before treatment initiation

  • Time-course studies capturing both acute and chronic effects

  • Dose-response relationships correlating with pharmacokinetic data

• Combined analytical approach:

  • Use MAPT (Ab-214) for total tau quantification

  • Pair with phospho-specific antibodies to distinguish between expression and modification effects

  • Complement with biochemical fractionation to assess soluble vs. insoluble tau pools

• Translational research applications:

  • Bridge findings between cell models, animal studies, and human samples

  • Validate target engagement across species

  • Correlate tau reduction with functional or behavioral improvements

This comprehensive approach using MAPT (Ab-214) Antibody provides critical insights into both the efficacy and mechanisms of tau-targeted therapeutics.

What is the optimal immunofluorescence protocol for MAPT (Ab-214) Antibody in brain tissue sections?

For optimal immunofluorescence staining of brain tissue sections with MAPT (Ab-214) Antibody, follow this detailed protocol:

Materials Required:

• MAPT (Ab-214) Antibody

• Appropriate fluorophore-conjugated secondary antibody

• PBS, pH 7.4

• Blocking solution (5% normal serum from same species as secondary antibody)

• 0.1-0.3% Triton X-100 in PBS

• Anti-fade mounting medium with DAPI

• Paraformaldehyde-fixed or methanol-fixed tissue sections

Procedure:

• Section preparation:

  • For fixed-frozen sections: Air-dry slides for 30 minutes at room temperature

  • For paraffin sections: Deparaffinize and rehydrate, then perform heat-induced epitope retrieval

• Permeabilization and blocking:

  • Wash sections 3× in PBS, 5 minutes each

  • Incubate in 0.3% Triton X-100 in PBS for 10 minutes

  • Block with 5% normal serum in PBS for 1 hour at room temperature

• Primary antibody incubation:

  • Dilute MAPT (Ab-214) Antibody 1:100-1:200 in blocking solution

  • Incubate overnight at 4°C in a humidified chamber

  • For co-staining, include compatible primary antibodies from different host species

• Washing and secondary antibody:

  • Wash 3× in PBS, 10 minutes each

  • Incubate with appropriate fluorophore-conjugated secondary antibody (1:500) for 2 hours at room temperature

  • Protect from light during and after this step

• Final processing:

  • Wash 3× in PBS, 10 minutes each

  • Counterstain with DAPI (1:10,000) for 5 minutes if not included in mounting medium

  • Mount with anti-fade medium and seal with nail polish

• Imaging considerations:

  • Capture images within 1-2 weeks of staining for optimal signal

  • Include z-stack imaging for accurate co-localization analysis

  • Store slides at 4°C in the dark to minimize photobleaching

This protocol can be adapted for different tissue preparation methods with appropriate modifications to the antigen retrieval and permeabilization steps.

How should researchers quantify and statistically analyze tau detection using MAPT (Ab-214) Antibody?

For rigorous quantification and statistical analysis of tau detection using MAPT (Ab-214) Antibody, researchers should follow these methodological guidelines:

Image Acquisition:

• Capture multiple representative fields per sample (minimum 5-10 fields)

• Maintain identical acquisition parameters across all experimental groups

• Include both positive and negative control samples in each imaging session

• Perform z-stack imaging when evaluating 3D structures

Quantification Approaches:

• For tissue sections:

  • Measure mean fluorescence intensity in defined anatomical regions

  • Count tau-positive cells as percentage of total cells

  • Assess area of positive staining normalized to total tissue area

• For cultured cells:

  • Analyze tau intensity per cell using automated cell segmentation

  • Measure subcellular distribution patterns (nuclear vs. cytoplasmic ratio)

  • Quantify co-localization with other markers using Pearson's or Manders' coefficients

Data Analysis Protocol:

• Test data for normality using Shapiro-Wilk or D'Agostino-Pearson test

• For normally distributed data: use parametric tests (t-test, ANOVA)

• For non-normally distributed data: use non-parametric alternatives (Mann-Whitney, Kruskal-Wallis)

• Apply appropriate multiple comparison corrections (Bonferroni, Tukey, FDR)

• Present data with appropriate visualization (box plots for non-parametric, bar graphs with individual data points for parametric)

Statistical Considerations:

• Use randomized block designs to control for experimental variability

• Include biological replicates (n ≥ 3) and technical replicates as appropriate

• Calculate effect sizes to assess biological significance beyond statistical significance

• Report exact p-values rather than threshold indicators (p<0.05)

This comprehensive quantification and analysis approach ensures robust, reproducible findings when using MAPT (Ab-214) Antibody for tau detection.

How can MAPT (Ab-214) Antibody be applied in humanized tau mouse models for Alzheimer's disease research?

The MAPT (Ab-214) Antibody offers valuable applications in humanized tau mouse models through these specialized approaches:

Humanized MAPT knock-in (KI) mice represent a significant advancement for studying tau biology and pathology in a physiologically relevant context. Research has demonstrated that combining MAPT humanization with APP mutations (App-NL-G-F/MAPT double KI mice) creates models exhibiting tau phosphorylation and amyloid pathology . For optimal application of MAPT (Ab-214) Antibody in these models:

• Pathological progression monitoring:

  • Track age-dependent changes in tau expression and distribution

  • Compare tau patterns between single MAPT KI and APP/MAPT double KI mice

  • Correlate tau alterations with behavioral or functional outcomes

• Comparative analytical approaches:

  • Use MAPT (Ab-214) to establish baseline total tau levels

  • Complement with phospho-specific antibodies (AT8, PHF-1, pS422) to assess pathological modifications

  • Implement these antibodies in adjacent tissue sections or multiplexed assays

• Specialized applications:

  • For dystrophic neurite analysis around Aβ plaques, use MAPT (Ab-214) in conjunction with amyloid markers

  • For regional vulnerability studies, quantify tau levels across different brain regions

  • For treatment response assessment, measure changes in total tau versus phospho-tau ratios

• Technical optimizations:

  • Age-dependent protocol modifications may be necessary as pathology develops

  • Consider antigen retrieval optimization for tissues with advanced pathology

  • Implement tau solubility fractionation to distinguish different tau pools

The cross-species reactivity of MAPT (Ab-214) Antibody makes it particularly valuable for comparative studies between humanized models and human patient samples, strengthening translational relevance.

What are the advantages and limitations of using MAPT (Ab-214) Antibody versus phospho-specific tau antibodies in neurodegenerative disease research?

Understanding the comparative advantages and limitations of MAPT (Ab-214) versus phospho-specific antibodies is critical for experimental design in neurodegenerative disease research:

Advantages of MAPT (Ab-214) Antibody:

• Comprehensive tau detection:

  • Recognizes total tau regardless of phosphorylation state

  • Provides baseline measurement for normalizing phospho-tau levels

  • Detects tau in both normal and pathological conditions

• Cross-species applications:

  • Reacts with human, mouse, and rat tau

  • Facilitates translational research between models and clinical samples

  • Enables comparative studies across different species models

• Methodological versatility:

  • Compatible with multiple applications (ELISA, IF)

  • Works with different sample preparations (methanol fixation validated)

  • Useful for monitoring total tau reduction in therapeutic studies

Limitations of MAPT (Ab-214) Antibody:

• Lack of pathology specificity:

  • Cannot distinguish between normal and pathological tau conformations

  • Does not specifically identify disease-associated modifications

  • Requires complementary approaches to assess pathological states

• Technical considerations:

  • As a polyclonal antibody, may exhibit lot-to-lot variability

  • Recognizes multiple tau isoforms, potentially complicating interpretation

  • May detect truncated tau forms differently than full-length protein

Complementary Use with Phospho-specific Antibodies:

Research demonstrates that combining MAPT (Ab-214) with phospho-specific antibodies like AT8, PHF-1, and pS422 provides more comprehensive insights than either approach alone . This combination enables:

• Distinguishing between changes in tau expression versus pathological modification

• Calculating phospho-tau to total tau ratios, a more informative metric of pathology

• Monitoring both therapeutic reduction of tau and modifications of remaining tau

The ideal approach integrates both antibody types in a strategic experimental design tailored to specific research questions.

How might MAPT (Ab-214) Antibody contribute to emerging tau-directed therapeutic approaches?

The MAPT (Ab-214) Antibody is positioned to make significant contributions to emerging tau-directed therapeutic research through several innovative applications:

• ASO therapeutic monitoring:
  Recent advances in antisense oligonucleotide therapy have shown promising results in reducing tau levels, with significant mRNA reduction (72% knockdown) and protein reduction (up to 55-80%) . The MAPT (Ab-214) Antibody provides an ideal tool for:

  • Quantifying total tau reduction in response to ASO therapy

  • Assessing regional differences in therapeutic response across brain regions

  • Monitoring long-term effects following single or multiple ASO administrations

• Combination therapy assessment:
  As therapeutic approaches evolve toward combination strategies, this antibody enables:

  • Evaluating synergistic effects between tau-reducing and anti-amyloid therapies

  • Assessing changes in tau distribution when combining ASOs with immunotherapies

  • Monitoring compensatory mechanisms following tau reduction

• Novel delivery system validation:
  For advancing delivery technologies, MAPT (Ab-214) can help:

  • Validate target engagement of novel BBB-crossing delivery systems

  • Assess cranial nerve delivery approaches being developed for CNS therapeutics

  • Quantify the efficiency of viral vector-mediated genetic therapies affecting tau

• Translational biomarker development:
  Beyond direct therapeutic assessment, this antibody can contribute to:

  • Correlating tissue tau levels with fluid biomarker measurements

  • Establishing relationships between regional tau reduction and functional outcomes

  • Developing imaging-pathology correlations to improve in vivo tau monitoring

• Personalized medicine approaches:
  The cross-species reactivity of MAPT (Ab-214) supports:

  • Patient-derived xenograft models to test individualized therapeutic approaches

  • Comparative studies between humanized models and patient samples

  • Ex vivo treatment response assessment in patient-derived tissue

These applications position MAPT (Ab-214) Antibody as a valuable tool in the rapidly evolving landscape of tau-directed therapeutics.

What novel experimental approaches might enhance the utility of MAPT (Ab-214) Antibody in future tau research?

Emerging technologies and experimental approaches promise to expand the utility of MAPT (Ab-214) Antibody in future tau research:

• Advanced microscopy integration:

  • Super-resolution microscopy to examine tau localization at nanoscale resolution

  • Expansion microscopy to physically enlarge samples for improved visualization

  • Live-cell imaging with antibody fragments to track tau dynamics in real time

• Single-cell applications:

  • Combining with single-cell transcriptomics to correlate protein and mRNA levels

  • Mass cytometry (CyTOF) integration for high-dimensional protein profiling

  • Spatial transcriptomics correlation with tau protein distribution

• Microfluidic organ-on-chip systems:

  • Implementing in 3D neuronal culture systems to study tau propagation

  • Analyzing tau in neurovascular unit models to assess blood-brain barrier interactions

  • Studying intercellular tau transfer in compartmentalized neuronal cultures

• Antibody engineering advancements:

  • Developing recombinant versions with enhanced specificity and reduced background

  • Creating site-specific labeled derivatives for multiplexed detection

  • Producing smaller antibody fragments (Fab, scFv) for improved tissue penetration

• Computational biology integration:

  • Machine learning analysis of tau distribution patterns across brain regions

  • Predictive modeling of tau pathology progression based on baseline measurements

  • Systems biology approaches linking tau to broader proteomic networks

• Novel methodology adaptation:

  • Implementing antibody in proximity ligation assays to study tau-protein interactions

  • Adapting for use in highly multiplexed imaging mass cytometry

  • Developing for CLARITY and other tissue clearing methods to study whole-brain tau distribution

These innovative approaches would significantly expand the research applications of MAPT (Ab-214) Antibody beyond its current validated uses in ELISA and immunofluorescence, potentially transforming our understanding of tau biology and pathology.